Ovarian Cancer Resource Center: Featured Article

Article

 

Ovarian Cancer: Is it Time for Personalized Approaches? 

 Ovarian cancer kills roughly 16,000 women each year. While the disease has traditionally been treated with surgery and chemotherapy, new targeted therapies show promise. This week our authors discuss and debate the

new treatment

approaches

, including the merits of

personalized medicine

.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content